Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2026
Event: Entry into a Material Definitive Agreement (Second Amendment to Loan and Security Agreement) with Oxford Finance LLC and other lenders.
Key Financial Metrics and Transaction Details
- Facility Expansion: The Credit Facility aggregate principal amount was expanded to up to $500.0 million.
- Immediate Funding (Term C Loan): $100.0 million funded upon execution.
- Available Funding (Term D Loan): Up to an additional $225.0 million available in increments of $50.0 million or more at lenders' discretion.
- Equity Consideration (Term C Warrants): Issued warrants to purchase 21,457 shares of Common Stock at an exercise price of $93.21 per share.
- Future Equity Consideration (Term D Warrants): Upon funding of Term D, warrants will be issued equal to 2.0% of the additional funding amount divided by a specific exercise price formula.
- Collateral: Company pledged all equity securities held in Poplar Therapeutics, Inc.
Material Changes Versus Prior Period
This filing represents a material amendment to the Loan and Security Agreement dated January 13, 2025, and previously amended on March 18, 2026. The primary change is the expansion of the credit facility capacity and the addition of new loan tranches (Term C and Term D) with associated warrant issuances. The filing does not provide comparative financial performance metrics (revenue, profit, cash flow) for the period.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release regarding the transaction, highlighting increased financial capacity and strategic flexibility. The filing includes standard forward-looking statements regarding clinical development, regulatory approvals, and capital requirements.
Risks and Contingencies:
- Future funding of the Term D Loan is subject to the lenders' sole discretion.
- Standard biotechnology risks apply, including clinical trial outcomes, regulatory approvals, and commercialization success.
- Warrant exercise prices are subject to adjustment for stock splits, dividends, and similar events.
Investor Verification Checklist
- Verify the exact terms of the Second Amendment filed as Exhibit 10.1.
- Confirm the current cash position and burn rate to assess the necessity of the additional $225.0 million Term D Loan.
- Review the valuation impact of the warrant issuance (21,457 shares at $93.21) and potential future dilution from Term D warrants.
- Assess the value and liquidity of the pledged equity in Poplar Therapeutics, Inc.
- Monitor the Company's ability to meet milestones required to trigger the discretionary funding of the Term D Loan.